{
    "id": 28261,
    "fullName": "EGFR G696_P1033dup",
    "impact": "duplication",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "EGFR G696_P1033dup indicates the tandem duplication of exons 18 through 25 of EGFR, resulting in duplication of the kinase domain (PMID: 26286086). G696_P1033dup results in constitutive activation of Egfr and a dramatic increase in colony formation relative to L858R in culture (PMID: 26286086).",
            "references": [
                {
                    "id": 4643,
                    "pubMedId": 26286086,
                    "title": "EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26286086"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 1956,
        "geneSymbol": "EGFR",
        "terms": [
            "EGFR",
            "ERBB",
            "ERBB1",
            "HER1",
            "mENA",
            "NISBD2",
            "PIG61"
        ]
    },
    "variant": "G696_P1033dup",
    "createDate": "05/13/2018",
    "updateDate": "09/10/2018",
    "referenceTranscriptCoordinates": {
        "id": 175994,
        "transcript": "NM_005228",
        "gDna": "chr7:g.55173945_55201340",
        "cDna": "c.2086_3099",
        "protein": "p.G696_P1033",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 4639,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tagrisso (osimertinib) inhibited EGFR phosphorylation and cell proliferation in transformed cells expressing kinase domain duplication mutant EGFR G696_P1033dup in culture (PMID: 26286086).",
            "molecularProfile": {
                "id": 29853,
                "profileName": "EGFR G696_P1033dup"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4643,
                    "pubMedId": 26286086,
                    "title": "EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26286086"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4641,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with lung adenocarcinoma harboring EGFR G696_P1033dup had a partial response after two cycles of Gilotrif (afatinib) after failing first line chemotherapy (PMID: 26286086).",
            "molecularProfile": {
                "id": 29853,
                "profileName": "EGFR G696_P1033dup"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4643,
                    "pubMedId": 26286086,
                    "title": "EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26286086"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4638,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tarceva (erlotinib) inhibited EGFR phosphorylation and cell proliferation in transformed cells expressing the kinase domain duplication mutant EGFR G696_P1033dup in culture (PMID: 26286086).",
            "molecularProfile": {
                "id": 29853,
                "profileName": "EGFR G696_P1033dup"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4643,
                    "pubMedId": 26286086,
                    "title": "EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26286086"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4640,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilotrif (afatinib) inhibited EGFR phosphorylation and cell proliferation in transformed cells expressing kinase domain duplication mutant EGFR G696_P1033dup in culture (PMID: 26286086).",
            "molecularProfile": {
                "id": 29853,
                "profileName": "EGFR G696_P1033dup"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4643,
                    "pubMedId": 26286086,
                    "title": "EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26286086"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4642,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with lung adenocarcinoma harboring EGFR G696_P1033dup had a partial response after two cycles of Gilotrif (afatinib), but subsequently developed resistance to the therapy after amplification of EGFR (PMID: 26286086).",
            "molecularProfile": {
                "id": 29854,
                "profileName": "EGFR G696_P1033dup EGFR amp"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 4643,
                    "pubMedId": 26286086,
                    "title": "EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26286086"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 29853,
            "profileName": "EGFR G696_P1033dup",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29854,
            "profileName": "EGFR G696_P1033dup EGFR amp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 175994,
            "transcript": "NM_005228",
            "gDna": "chr7:g.55173945_55201340",
            "cDna": "c.2086_3099",
            "protein": "p.G696_P1033",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}